GT201000143A - Inhibidores de beta-lactamasa - Google Patents

Inhibidores de beta-lactamasa

Info

Publication number
GT201000143A
GT201000143A GT201000143A GT201000143A GT201000143A GT 201000143 A GT201000143 A GT 201000143A GT 201000143 A GT201000143 A GT 201000143A GT 201000143 A GT201000143 A GT 201000143A GT 201000143 A GT201000143 A GT 201000143A
Authority
GT
Guatemala
Prior art keywords
lactamasa
inhibitors
beta
botterial
proliferation
Prior art date
Application number
GT201000143A
Other languages
English (en)
Inventor
Christopher J Burns
Randy W Jackson
Goswami Rajesh
Xu Hongyu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201000143A publication Critical patent/GT201000143A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A INHIBIDORES DE BETA-LACTAMASA LOS CUALES ACTUAN COMO INHIBIDORES DE LAS ENZIMAS DE BETA-LACTAMASA LO CUAL ES DE UTILIDAD PARA MEJORAR LA CAPACIDAD DE ACCIÓN DE CIERTAS SUSTANCIAS QUE INHIBEN LA PROLIFERACIÓN BACTERIANA TAL COMO LOS ANTIBIÓTICOS.
GT201000143A 2007-11-13 2010-05-13 Inhibidores de beta-lactamasa GT201000143A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US279707P 2007-11-13 2007-11-13

Publications (1)

Publication Number Publication Date
GT201000143A true GT201000143A (es) 2012-04-30

Family

ID=40344560

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000143A GT201000143A (es) 2007-11-13 2010-05-13 Inhibidores de beta-lactamasa

Country Status (21)

Country Link
US (2) US20100317621A1 (es)
EP (2) EP2220096A1 (es)
JP (2) JP2011503181A (es)
KR (2) KR20100109901A (es)
CN (2) CN101983203A (es)
AR (2) AR069310A1 (es)
AU (2) AU2008321443A1 (es)
BR (2) BRPI0820532A2 (es)
CA (2) CA2705393A1 (es)
CO (1) CO6331427A2 (es)
CR (1) CR11372A (es)
EA (2) EA201000775A1 (es)
EC (1) ECSP10010246A (es)
GT (1) GT201000143A (es)
IL (1) IL205205A0 (es)
MA (1) MA31874B1 (es)
MX (2) MX2010005252A (es)
TN (1) TN2010000203A1 (es)
TW (2) TW200930707A (es)
WO (2) WO2009064414A1 (es)
ZA (1) ZA201002467B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
AR076667A1 (es) * 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
JP6266978B2 (ja) 2010-08-10 2018-01-24 レンペックス・ファーマシューティカルズ・インコーポレイテッド 環状ボロン酸エステル誘導体およびその治療的使用
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
SG11201403254QA (en) 2011-12-22 2014-07-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
WO2013103760A1 (en) * 2012-01-06 2013-07-11 University Of South Florida Compositions, methods of use, and methods of treatment
US8933233B2 (en) * 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP2928898B1 (en) * 2012-12-07 2021-04-14 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EA201591004A1 (ru) 2013-01-04 2016-02-29 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
EP3139930A4 (en) * 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2016015093A (es) * 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
EP3882252A1 (en) 2014-06-11 2021-09-22 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EA201692301A1 (ru) * 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US10294246B2 (en) * 2014-10-01 2019-05-21 Merck Patent Gmbh Substituted boronic acids and boronate esters as immunoproteasome inhibitors
WO2016050356A1 (en) * 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
WO2016050355A1 (en) * 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10364257B2 (en) 2014-12-19 2019-07-30 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017222917A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Aliphatic prolinamide derivatives
BR112018077015B1 (pt) 2016-06-30 2022-05-03 Qpex Biopharma, Inc Derivados de ácido borônico e usos terapêuticos dos mesmos
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
JP2020510661A (ja) 2017-03-06 2020-04-09 ベナトルクス ファーマシューティカルズ，インク． β−ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019009369A1 (ja) * 2017-07-06 2019-01-10 大日本住友製薬株式会社 イミン誘導体
WO2019009370A1 (ja) * 2017-07-06 2019-01-10 大日本住友製薬株式会社 アミド誘導体
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2022511732A (ja) * 2018-11-29 2022-02-01 ベナトルクス ファーマシューティカルズ，インク． β－ラクタマーゼ阻害剤を含む組み合わせ組成物およびその使用
CN110156820B (zh) * 2019-04-25 2021-06-25 四川大学 一类巯基酰胺硼酸类衍生物及其作为mbl和/或sbl抑制剂的用途
WO2020257306A1 (en) 2019-06-19 2020-12-24 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112572B2 (en) * 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
JP2007505950A (ja) * 2003-06-10 2007-03-15 フルクラム・ファーマシューティカルズ・インコーポレーテッド β−ラクタマーゼ阻害剤およびその使用方法
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
AR076667A1 (es) * 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa

Also Published As

Publication number Publication date
CA2705393A1 (en) 2009-05-22
WO2009064413A1 (en) 2009-05-22
EP2220097A1 (en) 2010-08-25
BRPI0820531A2 (pt) 2012-07-10
TW200930707A (en) 2009-07-16
MA31874B1 (fr) 2010-11-01
CN101983203A (zh) 2011-03-02
CA2705389A1 (en) 2009-05-22
WO2009064414A1 (en) 2009-05-22
AR069310A1 (es) 2010-01-13
KR20100109901A (ko) 2010-10-11
ECSP10010246A (es) 2010-07-30
AU2008321444A1 (en) 2009-05-22
CR11372A (es) 2010-09-14
JP2011503181A (ja) 2011-01-27
EA201000774A1 (ru) 2010-12-30
MX2010005252A (es) 2011-04-11
TN2010000203A1 (en) 2011-11-11
BRPI0820532A2 (pt) 2012-07-10
EP2220096A1 (en) 2010-08-25
MX2010005250A (es) 2010-11-05
EA201000775A1 (ru) 2010-12-30
TW200936143A (en) 2009-09-01
US20100286092A1 (en) 2010-11-11
KR20100113485A (ko) 2010-10-21
ZA201002467B (en) 2011-02-23
US20100317621A1 (en) 2010-12-16
CO6331427A2 (es) 2011-10-20
JP2011504468A (ja) 2011-02-10
IL205205A0 (en) 2010-12-30
AU2008321443A1 (en) 2009-05-22
AR069463A1 (es) 2010-01-27
CN101861324A (zh) 2010-10-13

Similar Documents

Publication Publication Date Title
GT201000143A (es) Inhibidores de beta-lactamasa
GT201300124A (es) Inhibidores de nampt y rock
SMT201600085B (it) Piperidin-4-il azetidin derivati come inibitori di jak1
CO7151502A2 (es) Compuestos que inhiben la actividad de catecol o- metiltransferasa
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
CR20140024A (es) Compuestos inhibidores de metaloenzimas
ECSP12011654A (es) Derivados de 5-fluoropirimidinona
NZ730134A (en) Substituted tricyclic compounds as fgfr inhibitors
UY34177A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
CU20140025A7 (es) Pirimidinas anilladas sustituidas
UY33958A (es) Inhibidores de la glucosilceramida sintasa
GT201100322A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
BR112012018761A2 (pt) estruturas para prevenir fixação de microorganismos
CR20130616A (es) Amidas-2-piridina útiles como agonistas cb2
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
CR20140179A (es) 2-tiopirimidinonas
UY34466A (es) Proceso para estabilizar contenido bacteriano de treparaciones minerales acuosas que comprenden carbbonatos de calcio.